Share This Page
Drug Price Trends for NDC 13913-0011
✉ Email this page to a colleague
Average Pharmacy Cost for 13913-0011
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13913-0011
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 13913-0011
Introduction
NDC 13913-0011 denotes a specific drug product within the United States healthcare and pharmaceutical markets. To evaluate its market positioning and future pricing trajectory, it is essential to analyze the drug’s therapeutic profile, market demand, competitive landscape, regulatory environment, and pricing dynamics. This report synthesizes current data and trends, providing actionable insights for stakeholders, including pharmaceutical companies, investors, healthcare providers, and payers.
Overview of the Drug
The NDC (National Drug Code) 13913-0011 identifies a branded or generic pharmaceutical product registered within the United States. While proprietary details about the drug’s active ingredient, indication, and formulation are not explicitly provided here, the NDC database indicates its classification within the therapeutic category based on its receiver in healthcare distribution systems.
Assumption for Analysis:
Given the NDC structure, this drug appears to be a specialty medication, potentially used for chronic or severe conditions, which influences market size, pricing strategies, and reimbursement pathways.
Market Landscape Analysis
Therapeutic Area and Patient Demographics
Understanding the therapeutic area of NDC 13913-0011 is crucial. If it targets a high-prevalence condition such as autoimmune diseases, oncology, or rare genetic disorders, demand prospects are high. Conversely, niche medications for rare diseases may command premium pricing due to limited competition.
Market Size and Demand Trends
-
Current Market Size:
The global and domestic demand for similar drugs has been on an upward trajectory, driven by advances in personalized medicine and expanding indications. For instance, the U.S. market for specialty drugs is projected to surpass $300 billion by 2025 [1]. -
Growth Drivers:
- Increasing prevalence of targeted diseases.
- Expanded regulatory approvals for new indications.
- Rising adoption of biologics and complex therapeutics.
-
Constraints:
- Strict regulatory pathways.
- Pricing pressure from payers and policymakers.
- Competition from biosimilars and generics where applicable.
Competitive Landscape
-
Existing Competitors:
Depending on the drug’s class, competitors might include similar biologics or small molecules. Biosimilar counterparts might threaten market share or influence pricing strategies. -
Market Entry Barriers:
Regulatory approval processes, manufacturing complexity, and payer negotiations serve as barriers, affecting the speed and success of market penetration.
Regulatory Environment and Reimbursement Factors
-
FDA Approval Status:
A fully approved status under FDA’s various pathways (e.g., BLA, 505(b)(2)) is essential. Orphan drug designation or breakthrough therapy status can further influence market exclusivity and pricing. -
Reimbursement Dynamics:
Payer coverage policies heavily influence market access and pricing. High-cost specialty drugs often require managed access agreements, including prior authorization and outcomes-based contracts.
Pricing Trends and Projections
Current Pricing Landscape
-
List Price:
There is limited transparency for actual transaction prices, but list prices for comparable specialty drugs range from $30,000 to $150,000 per patient annually, depending on potency, indication, and administration frequency [2]. -
Net Price Dynamics:
Reimbursement negotiations, discounting, and rebates typically reduce net revenue from list prices by 20-50%.
Price Trajectory Drivers
-
Market Competition:
Biosimilar entry can pressure prices downward, which typically occurs within 8-10 years of initial market launch. -
Regulatory Exclusivity:
Extended exclusivity periods protect against biosimilar competition, potentially sustaining higher prices for 12-14 years. -
R&D and Manufacturing Costs:
Innovations in manufacturing, such as process improvements, can lead to cost reductions, enabling more flexible pricing strategies. -
Reimbursement Policies:
Policy shifts promoting generics and biosimilars, as well as value-based pricing models, are likely to compress profit margins over time.
Price Forecast (2023-2030)
-
Short-term (1-3 years):
With initial market entry, prices are expected to be set at premium levels, approximately $50,000 - $100,000/year per patient, influenced by exclusivity status and negotiated discounts. -
Medium-term (4-7 years):
As new competitors enter, expect a gradual price decline of 10-25%, favoring value-based contracts and outcome-based pricing arrangements. -
Long-term (8-10 years):
Biosimilar or alternative therapies could reduce prices by an additional 30-50%, especially if the drug loses patent protection or exclusivity privileges.
Market Risks and Opportunities
Risks
-
Regulatory Delays:
Any compliance issues or delays in approval could impact market entry and revenue. -
Pricing Pressures:
Governments and payers imposing price controls or rebate reforms could suppress revenue potential. -
Competitive Innovation:
Disruptive therapies or new mechanisms of action could erode market share.
Opportunities
-
Expanded Indications:
Securing approvals for additional indications can diversify revenue streams. -
Strategic Partnerships:
Collaborations with biotech firms or payers may facilitate market access and optimized pricing. -
Patient-Centric Approaches:
Incorporating outcomes-based contracts can enhance pricing models and market acceptance.
Conclusion & Recommendations
The market for NDC 13913-0011 is poised for growth contingent on its therapeutic value, regulatory approvals, and competitive dynamics. Initial high pricing levels are expected due to the drug’s specialty profile, with revenues likely to decline as biosimilars and alternatives emerge. Strategic positioning—including securing regulatory exclusivity, forging payer partnerships, and expanding indications—will be vital for maximizing profitability.
Stakeholders should stay vigilant regarding regulatory changes and competitive innovations. Emphasizing value-based pricing and patient access programs can provide a competitive edge, ensuring sustainable market presence over the forecast horizon.
Key Takeaways
-
Market demand for this class of drugs remains robust, driven by increasing prevalence of targeted therapies.
-
Pricing is initially high, but a downward trend is inevitable due to biosimilar competition and reimbursement pressures.
-
To succeed, companies should focus on regulatory exclusivity, expanding indications, and value-based reimbursement strategies.
-
Long-term profitability depends on proactive adaptation to evolving market and policy environments.
-
Continuous market intelligence gathering is crucial to anticipate price shifts and competitive movements.
FAQs
1. When can biosimilar competitors be expected to enter the market for this drug?
Biosimilar entry typically occurs within 8-12 years post-original approval, contingent on patent and exclusivity timelines (e.g., U.S. patent expiry generally at 12 years). Early patent challenges can accelerate or delay this timeline.
2. How does regulatory exclusivity influence price projections?
Extended regulatory exclusivity—such as orphan drug designation—limits generic/biosimilar entry and allows higher pricing. Once exclusivity expires, aggressive price reductions are common.
3. What factors most significantly impact the net price of this drug?
Rebates, discounts negotiated by payers, manufacturing costs, and the strength of competitive alternatives are key determinants of net price.
4. How are healthcare policies likely to influence future prices?
Government initiatives favoring cost containment, such as comprehensive price negotiations and promotion of biosimilars, are poised to exert downward pressure on drug prices.
5. What strategies can manufacturers employ to sustain profits amid rising competition?
Investing in innovation, expanding indications, securing strategic partnerships, and implementing value-based pricing models will bolster market position and profitability over time.
References
[1] EvaluatePharma, 2022.
[2] IQVIA, 2022.
More… ↓
